m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG00180)
Name
7-((1H-imidazol-1-yl)methyl)-4H-chromen-4-one
Synonyms
CHEMBL158984; 7-((1H-imidazol-1-yl)methyl)-4H-chromen-4-one; ZINC13861991; BDBM50097369; 7-Imidazol-1-ylmethyl-chromen-4-one
    Click to Show/Hide
Status
Investigative
Structure
Formula
C13H10N2O2
InChI
1S/C13H10N2O2/c16-12-3-6-17-13-7-10(1-2-11(12)13)8-15-5-4-14-9-15/h1-7,9H,8H2
InChIKey
KLOFOSXNENLIKT-UHFFFAOYSA-N
PubChem CID
10585323
TTD Drug ID
D0DJ3R
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Aromatase (CYP19A1)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Aromatase (CYP19A1) is a therapeutic target for 7-((1H-imidazol-1-yl)methyl)-4H-chromen-4-one. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 7-((1H-imidazol-1-yl)methyl)-4H-chromen-4-one through regulating the expression of Aromatase (CYP19A1). [1], [2]
References
Ref 1 Increased N6-methyladenosine causes infertility is associated with FTO expression. J Cell Physiol. 2018 Sep;233(9):7055-7066. doi: 10.1002/jcp.26507. Epub 2018 Mar 25.
Ref 2 A new class of nonsteroidal aromatase inhibitors: design and synthesis of chromone and xanthone derivatives and inhibition of the P450 enzymes aromatase and 17 alpha-hydroxylase/C17,20-lyase. J Med Chem. 2001 Mar 1;44(5):672-80. doi: 10.1021/jm000955s.